Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer's disease

Shiri Stempler, Keren Yizhak, Eytan Ruppin

Research output: Contribution to journalArticlepeer-review

Abstract

Accumulating evidence links numerous abnormalities in cerebral metabolism with the progression of Alzheimer's disease (AD), beginning in its early stages. Here, we integrate transcriptomic data from AD patients with a genome-scale computational human metabolic model to characterize the altered metabolism in AD, and employ state-of-the-art metabolic modelling methods to predict metabolic biomarkers and drug targets in AD. The metabolic descriptions derived are first tested and validated on a large scale versus existing AD proteomics and metabolomics data. Our analysis shows a significant decrease in the activity of several key metabolic pathways, including the carnitine shuttle, folate metabolism and mitochondrial transport. We predict several metabolic biomarkers of AD progression in the blood and the CSF, including succinate and prostaglandin D2. Vitamin D and steroid metabolism pathways are enriched with predicted drug targets that could mitigate the metabolic alterations observed. Taken together, this study provides the first network wide view of the metabolic alterations associated with AD progression. Most importantly, it offers a cohort of new metabolic leads for the diagnosis of AD and its treatment.

Original languageEnglish
Article numbere105383
JournalPLoS ONE
Volume9
Issue number8
DOIs
StatePublished - 15 Aug 2014

Fingerprint

Dive into the research topics of 'Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this